939426-21-8Relevant articles and documents
Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311)
Qiao, Jennifer X.,Wang, Tammy C.,Adam, Leonard P.,Chen, Alice Ye A.,Taylor, David S.,Yang, Richard Z.,Zhuang, Shaobin,Sleph, Paul G.,Li, Julia P.,Li, Danshi,Yin, Xiaohong,Chang, Ming,Chen, Xue-Qing,Shen, Hong,Li, Jianqing,Smith, Daniel,Wu, Dauh-Rurng,Leith, Leslie,Harikrishnan, Lalgudi S.,Kamau, Muthoni G.,Miller, Michael M.,Bilder, Donna,Rampulla, Richard,Li, Yi-Xin,Xu, Carrie,Lawrence, R. Michael,Poss, Michael A.,Levesque, Paul,Gordon, David A.,Huang, Christine S.,Finlay, Heather J.,Wexler, Ruth R.,Salvati, Mark E.
, p. 9010 - 9026 (2015/12/09)
Cholesteryl ester transfer protein (CETP) inhibitors raise HDL-C in animals and humans and may be antiatherosclerotic by enhancing reverse cholesterol transport (RCT). In this article, we describe the lead optimization efforts resulting in the discovery o
HETEROCYCLIC CETP INHIBITORS
-
Page/Page column 349-350, (2010/11/27)
Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
